Phaseline

Companies › Oligomerix

Oligomerix: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
OLX-07010
tau self-association inhibitor
MAPTPhase 1Alzheimer Disease–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05696483OLX-07010Phase 1Alzheimer DiseaseNeurologyMay 2026

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

MAPT (1)

Companies with the same targets

Eli Radiopharma Bristol-Myers Squibb Roche Voyager Therapeutics Amyloid Solution Arrowhead Pharmaceuticals Nuravax UCB Biopharma SRL

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.